Coming Soon to the United States

EndoPredict is a gene expression test that helps patients with breast cancer determine the best treatment option for their individual cancer.

The diagnostic test accurately determines the likelihood of cancer recurrence 10 years after diagnosis, allowing physicians to determine which patients can safely forgo chemotherapy.

For more information and future updates on EndoPredict please fill out the form below:

EndoPredict is a leading 2nd generation test in Europe that will soon be available in the United States.

Selected Publications: